Changeflow GovPing Healthcare & Life Sciences

Latest changes

GovPing monitors 375 sources across this category, representing 11% of GovPing's 3,276 total sources. These sources span six instrument types — Guidance, Enforcement, Rule, FAQ, Notice, and Consultation — and show 1,425 changes in the past 7 days. Sources

The California Board of Pharmacy issued 40+ license revocations in Q1 2026 and revoked 12 more licenses in Q2 2026. ANSM recalled six lots of MaaT013 fecal microbiota product due to a donor screening flaw and flagged a safety notice for Hologic mammography systems. Health Canada initiated a Type I recall for Philips MRI systems over software issues affecting liver stiffness measurements.

Favicon for changeflow.com

NCT07539597: CHW-Led Hypertension Study N=15, Single-Arm, Quasi-Experimental

NIH registered a new single-center, single-arm quasi-experimental feasibility study (NCT07539597) on ClinicalTrials.gov. The study will enroll 15 emergency department patients with asymptomatic hypertension and assess a community health worker (CHW)-led intervention addressing social determinants of health. Participants will complete SDOH surveys in REDCap with CHW-facilitated referrals to community organizations. Medical record review via EPIC and Healthix will evaluate healthcare utilization one year before and after the index ED visit.

Routine Notice Healthcare
Favicon for changeflow.com

Observational ICU Diaphragm Physiotherapy Trial NCT07538102

The NIH registered an observational clinical trial (NCT07538102) on April 20, 2026, evaluating whether respiratory physiotherapy protects diaphragm muscle structure in patients receiving mechanical ventilation in the ICU. The study compares standard ICU physiotherapy against neuromuscular electrical stimulation (NMES) as interventions, using ultrasonography to measure changes in diaphragm thickness. No compliance obligations are created by this trial registration.

Routine Notice Public Health
Favicon for changeflow.com

Peritoneal Dialysis Specialized LLM for PD Management

NIH registered a randomized controlled trial (NCT07539428) on ClinicalTrials.gov evaluating large language model-assisted workflows against physician-only decision-making for peritoneal dialysis management. The study uses clinical vignettes to assess quality differences and identify potential risks such as generating erroneous or harmful suggestions. Conditions include Peritoneal Dialysis and Large Language Models; interventions include a PD-specialized LLM and generalized LLM tools.

Routine Notice Healthcare
Favicon for changeflow.com

DCB vs DES Intervention Clinical Trial for Multivessel Coronary Artery Disease

NIH ClinicalTrials.gov registered a new prospective, multicenter, randomized clinical trial (NCT07539324) comparing drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) against drug-eluting stent-based PCI in patients with multivessel coronary artery disease. The trial will evaluate lesions measuring 2.25 mm to 4.0 mm in diameter using GENOSS DCB and second/third-generation drug-eluting stents.

Routine Notice Healthcare
Favicon for changeflow.com

Loss Aversion Messaging Effect on Exercise Adherence in Older Adults - NCT07540052

The NIH has registered a new clinical trial (NCT07540052) evaluating whether loss aversion messaging can improve exercise adherence in older adults with mobility disability. The 4-month study will enroll participants in a daily at-home strength training program and compare loss aversion messaging against standard adherence reminders. The trial will measure anticipated regret and exercise frequency as primary outcomes.

Routine Notice Healthcare
Favicon for changeflow.com

Phase 2 CAR-T Combined With ASCT for High-risk Relapsed/Refractory Large B-cell Lymphoma

The NIH has registered a Phase 2 clinical study (NCT07538635) evaluating axicabtagene ciloleucel combined with autologous stem cell transplantation (ASCT) in patients with relapsed/refractory large B-cell lymphoma (LBCL) who have high-risk factors. The trial is prospective, single-arm, single-center, and open-label. Axicabtagene ciloleucel is the sole intervention. ClinicalTrials.gov registrations are informational public listings and do not constitute regulatory approvals or enforceable obligations.

Routine Notice Healthcare
Favicon for changeflow.com

Observational Darolutamide ADT Study for Non-metastatic Prostate Cancer, China

NIH registered an observational study (NCT07538843) on ClinicalTrials.gov evaluating darolutamide combined with androgen deprivation therapy (ADT) in Chinese men with non-metastatic castration-resistant prostate cancer (nmCRPC) whose disease progressed following prior bicalutamide plus ADT treatment. The single-arm study aims to observe treatment efficacy and safety in approximately 75 participants over 36 months using standard-of-care darolutamide.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Phase 2 Peiyuan Guben Tongluo Ointment for Elderly Sarcopenia NCT07538674

The NIH ClinicalTrials.gov registry has published a Phase 2 clinical trial (NCT07538674) evaluating Peiyuan Guben Tongluo Ointment (Ejiao concentrated formula) for treatment of sarcopenia in elderly patients. The randomized, parallel-group study enrolls elderly sarcopenia patients and measures DXA-measured limb muscle mass increase from baseline after 12 weeks of treatment. The trial uses an agarose concentrating group as parallel control and includes exercise and nutritional intervention as co-interventions.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Phase 2 Dalpiciclib Radiotherapy Breast Cancer Brain Metastases

NIH registered Phase 2 clinical trial NCT07539753 evaluating brain radiotherapy combined with dalpiciclib and endocrine therapy in 46 HR-positive/HER2-negative advanced breast cancer patients with brain metastases. The prospective open-label study will assess safety and efficacy per RECIST v1.1, with clinic visits every 3 months until disease progression or withdrawal.

Routine Notice Pharmaceuticals
Favicon for dsps.wi.gov

GLP-1 Compounding Rules, Board Membership, Renewal Info

The Wisconsin Pharmacy Examining Board newsletter advises pharmacies dispensing compounded GLP-1 medications (such as semaglutide or tirzepatide) to ensure compliance with Wis. Admin. Code ch. Phar 15 requirements, including facility, process, documentation, and verification standards. The newsletter references FDA guidance warning that compounders may not produce drugs essentially copies of FDA-approved drugs unless documented shortages apply. The newsletter also announces the upcoming license renewal period opening April 12, 2026 and closing May 31, 2026, and notes that 2025 WI Act 167 will add two pharmacy technician seats to the Board.

Routine Notice Healthcare
Favicon for www.cms.gov

Medicare Preventive Services Codes Coverage Information

CMS Medicare Learning Network published MLN006559, an informational product providing codes and coverage information for Medicare preventive services. The publication includes links to related resources covering advance care planning, diabetes self-management training, Medicare Diabetes Prevention Program, Part D vaccines, wellness visits, and screening examinations.

Routine Notice Healthcare
Louisiana LDH News
Favicon for ldh.la.gov

Governor and LDH Secretary Urge Emotional Support After Shreveport Shooting

The Louisiana Department of Health and Governor Jeff Landry issued a public health notice encouraging residents to utilize the Louisiana 988 crisis hotline for free, confidential emotional support following a shooting in Shreveport. The notice provides information about available mental health resources including crisis support teams and behavioral health services. No compliance obligations or regulatory requirements are created.

Routine Notice Public Health
Favicon for changeflow.com

Pain Neuroscience Education Versus Kinesio Tape for Carpal Tunnel Syndrome

NIH ClinicalTrials.gov registered NCT07539480, a randomized controlled trial comparing Pain Neuroscience Education (PNE) versus Kinesio Tape for functional outcomes in patients with carpal tunnel syndrome. The study targets 160 participants with mild-to-moderate CTS, with an estimated completion date of April 20, 2026. This is an informational clinical trial registration with no compliance obligations.

Routine Notice Healthcare
Favicon for changeflow.com

The Effect of Coffee Consumption on Balance, University Students

NIH registered an observational study (NCT07540559) investigating the effects of daily coffee consumption on balance performance in healthy university students. Participants will be categorized by habitual caffeine intake and assessed using standardized clinical balance tests. The study focuses on whether caffeine influences neuromuscular control, reaction time, and postural stability.

Routine Notice Public Health
Favicon for changeflow.com

ANS02 Phase 1 Study for EGFR Mutation-Positive NSCLC

NIH registered a first-in-human Phase 1 clinical trial (NCT07538804) evaluating ANS02 monotherapy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). The multi-center, open-label study will assess safety, tolerability, preliminary efficacy, pharmacokinetics, and anti-tumor activity. This registration documents the trial on ClinicalTrials.gov, supporting transparency requirements for federally funded clinical research.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Chlorhexidine vs Morus Nigra Mouthwash Periodontal Trial

NIH ClinicalTrials.gov has registered study NCT07540624, a randomized controlled trial evaluating the comparative efficacy of chlorhexidine gluconate (0.12%) and Morus nigra (blackberry, 5%) mouthwashes as adjuncts to non-surgical periodontal treatment. The study will enroll patients with periodontitis across three arms: scaling and root planing (SRP) alone, SRP plus chlorhexidine, and SRP plus Morus nigra mouthwash. Investigators will assess clinical periodontal parameters, gingival crevicular fluid inflammatory markers (TNF-a, IL-1b, IL-10), and subgingival plaque microbiological profiles at baseline, 1 month, and 3 months.

Routine Notice Healthcare
Favicon for changeflow.com

Intestinal Ultrasound Predicts Crohn's Disease Relapse in Deep Remission

NIH registered a multicenter prospective observational study evaluating transabdominal intestinal ultrasound as a non-invasive predictor of Crohn's disease relapse. The 18-month study will follow CD patients in deep remission, comparing color Doppler ultrasound parameters between relapse and non-relapse groups using stratified analysis by Montreal classification to establish a predictive model.

Routine Notice Healthcare
Favicon for changeflow.com

Randomized Controlled Study on Mandala Coloring for Quality of Life in Epilepsy

NIH registered a randomized controlled trial (NCT07540013) to assess mandala painting's effect on quality of life in epilepsy patients. The single-blind study at Gümüşhane State Hospital Neurology Polyclinic will enroll adult patients with generalized epilepsy, randomly assigning them to control or experimental groups via full simple randomization. The experimental group will receive mandala painting materials and instructions to complete one mandala at home three times weekly over twenty-four sessions, with data collected using the QOLIE-31 quality-of-life scale.

Routine Notice Public Health
Favicon for changeflow.com

The REACH-OUT Trial - Blood Pressure Optimization for Women

NIH registered a new clinical trial (NCT07540143) titled the REACH-OUT Trial on ClinicalTrials.gov. The trial will test a technology-enabled strategy to optimize blood pressure among reproductive-aged women with hypertension receiving care at Federally Qualified Health Centers. The study will evaluate health literacy-informed education materials, BP monitors, portal tools, MeDS assessment, and patient navigator support.

Routine Notice Healthcare
Favicon for changeflow.com

Roy Model Medication Training Heart Failure Trial

NIH registered clinical trial NCT07538596 on ClinicalTrials.gov evaluating an Ignite-Based Medication Management Training program for heart failure patients. The trial will enroll participants with heart failure with reduced ejection fraction (HFrEF), randomizing them to receive structured medication training via WhatsApp or standard discharge education. Participants will be followed for 12 weeks with questionnaires at baseline, 4 weeks, and 12 weeks to assess medication adherence and symptom management outcomes.

Routine Notice Healthcare
Favicon for changeflow.com

Motivational Interviewing Prevents Early Childhood Caries, 228 Mother-Infant Pairs, Malaysia

NIH ClinicalTrials.gov registered a two-arm parallel cluster-randomized controlled trial (NCT07538219) in Malaysia comparing Motivational Interviewing-based Anticipatory Guidance versus conventional Ministry of Health Anticipatory Guidance for preventing early childhood caries. The study will recruit 228 mother-infant pairs from MOH Maternal and Child Health Clinics in Setiu and Hulu Terengganu, with data collection at infant ages 6, 9, and 12 months.

Routine Notice Healthcare
Favicon for changeflow.com

Fuchs Dystrophy Descemet Polishing Clinical Trial NCT07539012

The NIH ClinicalTrials.gov registry has posted a new clinical trial (NCT07539012) titled 'Effect of Descemet Membrane Polishing in Fuchs Endothelial Corneal Dystrophy.' The study will evaluate whether polishing the Descemet membrane prior to cultured endothelial cell injection improves guttae removal and cell adhesion in Fuchs dystrophy patients. Corneal endothelial keratoplasty is currently the reference treatment, but graft shortages have driven interest in cell-based therapies.

Routine Notice Healthcare
Favicon for changeflow.com

Comparison of 7-Day vs 1-Day Packaging for SQ-LNS in Ethiopia

NIH ClinicalTrials.gov registered a mixed-methods field study (NCT07540793) comparing 7-day (7dp) vs 1-day (1dp) packaging of Small Quantity Lipid-based Nutrient Supplements (SQ-LNS) for children 6-24 months in North Shoa Zone, Amhara Region, Ethiopia. The study, conducted by Edesia Nutrition in partnership with Nutriset Développement, will evaluate acceptability and adherence to the new packaging design. The new 140g 7dp packet reduces cost by over 15% through 40% less packaging and 20% improved transportation efficiency.

Routine Notice Public Health
Favicon for changeflow.com

Randomized Trial of Tranexamic Acid and Sucralfate for Gastrointestinal Tumor Bleeding

NIH registered Clinical Trial NCT07540026, a randomized controlled trial evaluating endoscopic application of tranexamic acid and sucralfate powders for hemostasis in gastrointestinal tumor bleeding. The study will recruit 60 patients at National Cheng Kung University Hospital in Taiwan, comparing active treatment (3g sucralfate powder and 1.5g tranexamic acid powder) against standard treatment. The trial is listed as ongoing with an estimated completion date of April 20, 2026.

Routine Notice Healthcare
Favicon for changeflow.com

Factors Affecting Immediate Anterior Implants: Retrospective Clinical Study

The NIH ClinicalTrials.gov registry has posted a retrospective cohort study (NCT07539168) evaluating clinical, surgical, and prosthetic factors associated with outcomes of immediate implant placement in the anterior maxilla. The observational study aims to identify predictors of implant survival and complications within 12 months of placement, and will assess peri-implant marginal bone loss, prosthetic complications, and esthetic outcomes using the pink esthetic score.

Routine Notice Healthcare
Favicon for changeflow.com

Biomarker Panel Forecasts Chronic GVHD After Allo-HSCT

NIH registered a single-center observational clinical study (NCT07539220) investigating a biomarker panel for forecasting chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The discovery cohort enrolled 1000 consecutive patients retrospectively from January 2021 to June 2023, while a validation cohort of 500 recipients was enrolled from June 2023 to June 2024. Heparinized blood samples were collected at day +90 post-HSCT and analyzed using multiplex mass spectrometry with pooled plasma to compare proteomic profiles between patients with and without cGVHD.

Routine Notice Healthcare
Favicon for changeflow.com

Telerehabilitation in Patients With Bronchiectasis

The NIH registered a new randomized controlled trial (NCT07539571) on ClinicalTrials.gov evaluating home-based telerehabilitation for patients with bronchiectasis. The single-center trial will be conducted at Virgen del Rocío University Hospital in Spain, randomizing participants to usual care or a 12-week supervised telerehabilitation program three times per week. Outcome measures include the 6-minute walk test, quality-of-life questionnaires, pulmonary function tests, and inflammatory biomarkers.

Routine Notice Healthcare
Favicon for changeflow.com

HBVCare Mobile App Chronic Hepatitis B Treatment Adherence Randomized Controlled Trial

NIH registered clinical trial NCT07540637, a multicenter randomized controlled trial evaluating the HBVCare mobile application for improving treatment adherence in chronic Hepatitis B patients at Hoang Long Clinic and Hanoi Medical University Hospital in Vietnam. Patients are randomized to standard care or HBVCare app intervention, with adherence outcomes assessed at three months.

Routine Notice Public Health
Favicon for changeflow.com

Celsio Cryocatheter Disposable System Bronchoscopy Study

NIH registered a new clinical trial on ClinicalTrials.gov evaluating the Celsio Disposable Cryocatheter System for diagnostic and interventional bronchoscopy in patients with lung cancer and interstitial lung disease. The study aims to generate real-world evidence on device performance and identify best practices without interfering with standard clinical care.

Routine Notice Healthcare
Favicon for changeflow.com

Functionally Optimized CD33 CAR-T for AML, Phase 1 Trial NCT07538713

NIH registers Phase 1 trial NCT07538713 evaluating functionally optimized CD33 CAR-T (FO33 CAR-T) cell therapy in patients with recurrent/refractory acute myeloid leukemia (AML). The single-arm study will assess safety, tolerability, and preliminary efficacy of the CD33-targeted therapy. CD33 is expressed in leukemia cells from over 80% of AML patients and was selected as the target antigen due to higher expression levels across AML subtypes compared to alternative targets such as CLL-1 and CD123.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Investigation of Patients Presenting With Acute Functional Neurological Symptoms

NIH ClinicalTrials.gov registered NCT07538414, a retrospective single-center observational study analyzing patients presenting with acute functional neurological symptoms. The study aims to characterize the frequency, clinical features, diagnostic pathways, and healthcare utilization of patients with functional neurological disorder. Data collection is limited to retrospective patient data review; no prospective interventions are involved.

Routine Notice Healthcare
IN Dept of Health
Favicon for www.in.gov

Technical Review Panel Public Meeting Notice

Indiana Department of Health has posted a public meeting notice for the Technical Review Panel. The meeting is scheduled for Friday, March 27, 2026, at 10 a.m. EST in the Robert O. Yoho Board Room at 2 N. Meridian St., Indianapolis, IN 46204. Virtual attendance options via Microsoft Teams and telephone are available.

Routine Notice Public Health
Favicon for changeflow.com

Hospital Violence Intervention Program (HVIP+) Community Model, Central Arkansas

The National Institutes of Health has registered a new clinical trial (NCT07539142) testing the preliminary efficacy of a Hospital-based Violence Intervention Program (HVIP) in Central Arkansas. The optimization randomized control trial will evaluate interventions including Brief Bedside, Peer Support, Case Management with Voucher, and SELF Group Therapy Sessions for hospital-based violence intervention, community firearm violence, and firearm behaviors.

Routine Notice Healthcare
Favicon for changeflow.com

Observational Safety Trial of CT0494BCP in Advanced Gastric/Esophagogastric Junction Adenocarcinoma

A new observational safety trial (NCT07538856) evaluating CT0494BCP cell therapy in participants with advanced gastric/esophagogastric junction adenocarcinoma has been registered on ClinicalTrials.gov. The study uses Bayesian optimal interval (BOIN) design for dose escalation across six dose groups. CT0494 cells are assigned to three escalating doses (3.0×10⁸, 4.5×10⁸, 6.0×10⁸), and CT7095 cells to two escalating doses (1.5×10⁸, 3.0×10⁸). The trial will assess safety, tolerability, preliminary efficacy, and cellular metabolism kinetics.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Effectiveness of Ambulatory Transcutaneous Tibial Nerve Stimulation for Overactive Bladder

NIH has registered a randomized clinical trial (NCT07540273) comparing ambulatory versus clinic-based transcutaneous tibial nerve stimulation for treating overactive bladder in adults aged 18-65. The two-arm study will enroll participants receiving identical electrical stimulation parameters (20 Hz, 200 µs) delivered either at home via portable device or in-clinic twice weekly over 2 weeks. The trial will assess urgency episode frequency, bladder symptoms, and quality of life outcomes.

Routine Notice Public Health
Favicon for changeflow.com

WECARE Study, Chinese American Dementia Caregivers

NIH has registered a new clinical trial, NCT07539350, titled 'WECARE Study,' testing a seven-week multimedia wellness intervention for Chinese American family caregivers of persons with Alzheimer's disease and related dementias. The trial aims to determine whether the WECARE program improves caregiver well-being and reduces stress related to caregiving for persons with caregiver burden. The study does not create compliance obligations for regulated entities.

Routine Notice Healthcare
Favicon for changeflow.com

Effect of Internal Jugular Vein Catheterization on Intracranial Pressure and Intracranial Blood Flow

The National Institutes of Health registered a prospective observational clinical study (NCT07540481) evaluating the effect of internal jugular vein catheterization on intracranial pressure using optic nerve sheath diameter measurements and carotid artery Doppler ultrasonography in adult patients undergoing surgery under general anesthesia. The study will assess ONSD changes at two time points and secondary Doppler parameters. No compliance obligations or deadlines are imposed by this registration.

Routine Notice Healthcare
Favicon for changeflow.com

Pilot RCT Tests ACT for Perinatal Loss Mental Health

NIH registered a pilot randomized controlled trial (NCT07538011) evaluating an Acceptance and Commitment Therapy-based psychosocial intervention for women who have experienced perinatal loss. The 4-week mixed-format program includes four in-person sessions and two videoconferencing sessions, with a 30-minute booster one month post-completion. The study will assess feasibility, acceptability, and preliminary effects on perinatal grief, PTSD, depression, anxiety, psychological flexibility, and social support.

Routine Notice Healthcare
Favicon for changeflow.com

Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)

NIH ClinicalTrials.gov has registered a single-arm, open-label Phase I exploratory study (NCT07538479) evaluating controlled cold exposure combined with standard PD-1/PD-L1 inhibitor-based therapy in 24 participants with solid malignancies. The primary objectives are to evaluate safety, tolerability, and feasibility of the cold exposure intervention. Secondary objectives include exploring preliminary antitumor activity and effects on brown adipose tissue activation, peripheral immune profiling, circulating cytokines, metabolomics, gut microbiota, and tumor biomarkers.

Routine Notice Healthcare
Favicon for changeflow.com

HDM2024 Phase 1 Trial, Advanced Solid Tumors

NIH registered a Phase 1 clinical trial (NCT07539285) for HDM2024, an investigational drug, in participants with advanced solid tumors. The trial will evaluate drug safety, tolerability, and antitumor activity. Participants receive the study drug once every three weeks, with imaging-based efficacy assessments every six weeks.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Bambini Kids Robot-Assisted Gait Training Safety and Effectiveness Trial in Children With Cerebral Palsy

NIH has registered a clinical trial evaluating the safety and effectiveness of the Bambini Kids pediatric robotic exoskeleton in children with cerebral palsy (CP). The single-arm study will assess robot-assisted gait training (RAGT) as an intervention for gait impairment and motor performance limitations in the pediatric CP population. The trial is registered as NCT07539389 with an estimated completion date of April 20, 2026.

Routine Notice Medical Devices
Favicon for changeflow.com

Ultrasound-Guided Percutaneous Needle Tenotomy vs Percutaneous Ultrasonic Needle Tenotomy for Gluteal Tendinosis

NIH ClinicalTrials.gov registered a new clinical study (NCT07540806) comparing two tenotomy techniques for gluteal tendinosis: standard percutaneous needle tenotomy (PNT) versus percutaneous ultrasonic tenotomy (PUT) using the Tenex device. The study's primary endpoints are pain improvement and functional outcomes. This is an informational database entry; no regulatory obligations or compliance requirements are created.

Routine Notice Healthcare
Minnesota DOH News
Favicon for www.health.state.mn.us

Youth Cannabis Use Continued to Decline in 2025

The Minnesota Department of Health released findings from the 2025 Minnesota Student Survey showing 96% of students reported not using cannabis in the last month, and a 57.7% decrease in past 12-month use among eighth, ninth, and 11th graders since 2013. The survey, conducted between January and June 2025, is Minnesota's first since adult cannabis use was legalized in 2023.

Routine Notice Public Health
Favicon for changeflow.com

AI-Guided Atrial Fibrillation Detection After Ischemic Stroke: Prospective Randomized Trial

NIH registered a prospective randomized trial (NCT07540065) comparing AI-guided atrial fibrillation risk stratification plus intensified rhythm monitoring (wearable devices, extended ECG patches) against standard care in post-ischemic stroke patients. The trial enrolls an Active Follow-up Group and a Standard Follow-up Group, with conditions including Atrial Fibrillation, Stroke, and Artificial Intelligence. The primary hypothesis is that AI-assisted ECG analysis will significantly increase AF detection rates and enable earlier anticoagulation decisions while reducing unnecessary bleeding risk exposure.

Routine Notice Healthcare
Favicon for changeflow.com

VALsartan on atRIAl Mitral Regurgitation Pilot Randomized Controlled Trial Phase 2

NIH ClinicalTrials.gov registered a Phase 2 pilot randomized controlled trial (NCT07539298) evaluating valsartan versus placebo for treatment of atrial functional mitral regurgitation in adults with preserved left ventricular ejection fraction. The 12-month study will assess progression reduction, mitral valve leaflet remodeling, and safety/tolerability. Participants will undergo 3D echocardiography, 6-minute walk tests, and Kansas City Cardiomyopathy Questionnaire assessments.

Routine Notice Healthcare
Favicon for changeflow.com

BPS-Tech Pilot Trial for Eighth Graders

NIH has registered a pilot clinical trial (NCT07540819) testing a single-session writing exercise called Best Possible Self-Tech (BPS-Tech) with eighth graders. The study aims to assess feasibility and acceptability of classroom delivery, and to examine associations between textual features and positive affect outcomes.

Routine Notice Healthcare
Favicon for changeflow.com

Observational TFESI Efficacy in Lumbar Radicular Pain

NIH registered an observational study (NCT07538765) evaluating the effectiveness of transforaminal epidural steroid injections (TFESI) in patients aged 18 to 90 with radicular low back pain caused by lumbar disc herniation who did not improve with conservative treatment. The three-month study tracks pain reduction using the Visual Analog Scale and functional improvement using the Oswestry Disability Index. No compliance obligations or deadlines are created by this registry entry.

Routine Notice Public Health
Favicon for changeflow.com

Virtual Intervention for Behavioral Health in Emerging Adults; VIBE in the Parks

NIH ClinicalTrials.gov has registered a randomized clinical trial (NCT07539636) evaluating a digital behavioral health intervention, 'VIBE in the Parks', for adolescents and young adults experiencing anxiety and depression. The study will be conducted at four Chicago Park District sites, comparing the digital treatment to a control condition using a digital workbook.

Routine Notice Public Health
Favicon for changeflow.com

QI-019B Phase 1 Trial for Relapsed/Refractory Multiple Myeloma

NIH registered Phase 1 trial NCT07539233 evaluating QI-019B Injection in patients with relapsed/refractory multiple myeloma. The single-arm, open-label, single-center study will assess safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the investigational drug.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Optimizing Early Nutrition Management of Extremely and/or Very Preterm Infants

NIH ClinicalTrials.gov has registered a clinical quality improvement study (NCT07538999) evaluating an early nutrition management bundle for extremely and/or very preterm infants. The bundle combines three interventions: individualized human milk feeding, early enteral zinc supplementation, and routine parenteral carnitine supplementation. The study will assess clinical outcomes including growth, organ function, and neurodevelopment compared to routine nutritional strategies.

Routine Notice Public Health

Showing 1–50 of 6,952 changes

1 2 3 140
RSS

Get daily alerts for healthcare & life sciences

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

Filters

375 official sources tracked

USPTO Trademarks - Medical Services (Class 044)

Updated 17d ago

USPTO Patent Grants - Diagnosis & Surgery (A61B)

Updated 6d ago

ClinicalTrials.gov Studies

Updated 23m ago

USPTO Trademarks - Medical Devices (Class 010)

Updated 17d ago

USPTO Trademarks - Pharmaceuticals (Class 005)

Updated 17d ago

USPTO Patent Applications - Pharma (A61K)

Updated 7d ago

Regs.gov: Food and Drug Administration

Updated 2d ago

JD Supra Healthcare

Updated 1d ago

USPTO Patent Applications - Medical Devices (A61M)

Updated 7d ago

USPTO Patent Applications - Biotech (C12N)

Updated 6d ago

USPTO Patent Applications - Prosthetics (A61F)

Updated 7d ago

USPTO Patent Grants - Prosthetics (A61F)

Updated 6d ago

USPTO Patent Applications - Peptides (C07K)

Updated 7d ago

USPTO Patent Applications - Organic Chemistry (C07D)

Updated 9d ago

USPTO Patent Grants - Therapeutics (A61P)

Updated 7h ago

USPTO Patent Applications - Therapeutics (A61P)

Updated 7d ago

USPTO Patent Grants - Organic Chemistry (C07D)

Updated 6d ago

USPTO Patent Grants - Peptides (C07K)

Updated 3d ago

USPTO Patent Applications - Health Informatics (G16H)

Updated 10d ago

USPTO Patent Applications - Diagnosis & Surgery (A61B)

Updated 18d ago

ANSM Drug & Device Safety Alerts

Updated 1h ago

FR: National Institutes of Health

Updated 2d ago

Regs.gov: Centers for Medicare and Medicaid Services

Updated 4d ago

FR: Health and Human Services Department

Updated 2d ago

Health Canada Recalls & Safety Alerts

Updated 4d ago

FR: Food and Drug Administration

Updated 2d ago

EPO Patent Bulletin - Pharma (A61K)

Updated 1d ago

EPO Patent Bulletin - Biotech (C12N)

Updated 1d ago

EPO Patent Bulletin - Health Informatics (G16H)

Updated 1d ago

USPTO Patent Grants - Medical Devices (A61M)

Updated 3d ago

USPTO Patent Grants - Health Informatics (G16H)

Updated 1d ago

EPO Patent Bulletin - Diagnosis & Surgery (A61B)

Updated 1d ago

South Carolina DPH News

Updated 3d ago

EPO Patent Bulletin - Medical Devices (A61M)

Updated 4d ago

WHO News

Updated 2d ago

Hawaii DOH News

Updated 7d ago

CMS Newsroom

Updated 10d ago

FR: Centers for Medicare & Medicaid Services

Updated 2d ago

IN Dept of Health

Updated 19m ago

FR: Centers for Disease Control and Prevention

Updated 6d ago

FR: Children and Families Administration

Updated 3d ago

Regs.gov: Drug Enforcement Administration

Updated 17d ago

Regs.gov: Administration of Children and Families

Updated 12d ago

FDA Medical Device Recalls

Updated 4d ago

NY DOH Press Releases 2026

Updated 3d ago

Oregon OHA News

Updated 4d ago

North Carolina DHHS News

Updated 3d ago

HSA Singapore Announcements

Updated 5d ago

DEA Press Releases

Updated 3d ago

EPO Patent Bulletin - Organic Chemistry (C07D)

Updated 3d ago

EPO Patent Bulletin - Peptides (C07K)

Updated 20h ago

Medicaid State Plan Amendments

Updated 20d ago

Saudi SFDA News

Updated 6d ago

Wales CIW News

Updated 3d ago

DEA Public Safety Alerts

Updated 4d ago

New Mexico DOH News

Updated 2d ago

Louisiana LDH News

Updated 5d ago

RI DOH News

Updated 1d ago

MT Dept of Public Health News

Updated 6d ago

FR: Health Resources and Services Administration

Updated 2d ago

Get Healthcare & Life Sciences alerts

Daily digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get Healthcare & Life Sciences alerts

We'll email you when new healthcare & life sciences changes are detected.

Free. Unsubscribe anytime.

You're subscribed!